Avecho Biotechnology Limited ((AU:AVE)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: Avecho Biotechnology Limited is conducting a Phase III clinical study titled A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of CBD TPM Capsules in Adults for Use in the Reduction of Insomnia Severity. The study aims to assess the effectiveness and safety of CBD TPM capsules in reducing insomnia severity, a common sleep disorder affecting daily functioning.
Intervention/Treatment: The study tests nightly doses of Cannabidiol (CBD) capsules, specifically 75mg and 150mg, against a placebo. The purpose is to determine if these doses improve sleep quality over an eight-week period.
Study Design: This interventional study uses a randomized, parallel assignment model with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded. The primary goal is treatment-focused.
Study Timeline: The study began on April 23, 2023, with recruitment currently ongoing. The last update was submitted on June 4, 2025. These dates are crucial for tracking the study’s progress and ensuring timely results.
Market Implications: This study could significantly impact Avecho Biotechnology’s stock performance and investor sentiment, especially if results show a positive effect of CBD on insomnia. As the market for sleep disorder treatments grows, successful outcomes could position Avecho as a leader, influencing competitors in the industry.
The study is ongoing, with further details available on the ClinicalTrials portal.